Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Douglas D. L., Duckworth T., Russell R. G., Kanis J. A., Preston C. J., Preston F. E., Prenton M. A., Woodhead J. S. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet. 1980 May 17;1(8177):1043–1047. doi: 10.1016/s0140-6736(80)91496-8. [DOI] [PubMed] [Google Scholar]
- Mundy G. R., Rick M. E., Turcotte R., Kowalski M. A. Pathogenesis of hypercalcemia in lymphosarcoma cell leukemia. Role of an osteoclast activating factor-like substance and a mechanism of action for glucocorticoid therapy. Am J Med. 1978 Oct;65(4):600–606. doi: 10.1016/0002-9343(78)90847-1. [DOI] [PubMed] [Google Scholar]
- Ryzen E., Martodam R. R., Troxell M., Benson A., Paterson A., Shepard K., Hicks R. Intravenous etidronate in the management of malignant hypercalcemia. Arch Intern Med. 1985 Mar;145(3):449–452. [PubMed] [Google Scholar]
- Seyberth H. W., Segre G. V., Morgan J. L., Sweetman B. J., Potts J. T., Jr, Oates J. A. Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. N Engl J Med. 1975 Dec 18;293(25):1278–1283. doi: 10.1056/NEJM197512182932502. [DOI] [PubMed] [Google Scholar]
- van Breukelen F. J., Bijvoet O. L., van Oosterom A. T. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet. 1979 Apr 14;1(8120):803–805. doi: 10.1016/s0140-6736(79)91319-9. [DOI] [PubMed] [Google Scholar]